Targeting mitochondrial metabolism for metastatic cancer therapy.

Abstract

Primary tumors evolve metabolic mechanisms favoring glycolysis for adenosine triphosphate (ATP) generation and antioxidant defenses. In contrast, metastatic cells frequently depend on mitochondrial respiration and oxidative phosphorylation (OxPhos). This reliance of metastatic cells on OxPhos can be exploited using drugs that target mitochondrial metabolism. Therefore, therapeutic agents that act via diverse mechanisms, including the activation of signaling pathways that promote the production of reactive oxygen species (ROS) and/or a reduction in antioxidant defenses may elevate oxidative stress and inhibit tumor cell survival. In this review, we will provide (1) a mechanistic analysis of function-selective extracellular signal-regulated kinase-1/2 (ERK1/2) inhibitors that inhibit cancer cells through enhanced ROS, (2) a review of the role of mitochondrial ATP synthase in redox regulation and drug resistance, (3) a rationale for inhibiting ERK signaling and mitochondrial OxPhos toward the therapeutic goal of reducing tumor metastasis and treatment resistance. Recent reports from our laboratories using metastatic melanoma and breast cancer models have shown the preclinical efficacy of novel and rationally designed therapeutic agents that target ERK1/2 signaling and mitochondrial ATP synthase, which modulate ROS events that may prevent or treat metastatic cancer. These findings and those of others suggest that targeting a tumor's metabolic requirements and vulnerabilities may inhibit metastatic pathways and tumor growth. Approaches that exploit the ability of therapeutic agents to alter oxidative balance in tumor cells may be selective for cancer cells and may ultimately have an impact on clinical efficacy and safety. Elucidating the translational potential of metabolic targeting could lead to the discovery of new approaches for treatment of metastatic cancer.

• Authors: Antonino Passaniti, Myoung Sook Kim, Brian M Polster, Paul Shapiro
• Journal: Molecular carcinogenesis (Mol Carcinog) Vol. 61 Issue 9 Pg. 827-838 (09 2022) ISSN: 1098-2744 [Electronic] United States
• PMID: 35723497 (Publication Type: Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Antioxidants
• Reactive Oxygen Species
• Adenosine Triphosphate
• Mitochondrial Proton-Translocating ATPases

Topics

• Adenosine Triphosphate (metabolism)
• Antioxidants
• Humans
• Mitochondria (metabolism)
• Mitochondrial Proton-Translocating ATPases (metabolism)
• Neoplasms (metabolism)
• Oxidative Phosphorylation
• Reactive Oxygen Species (metabolism)